Multiple myeloma (MM) is a B-cell neoplasm characterized by bone marrow infiltration with malignant plasma cells, which synthesize and secrete monoclonal immunoglobulin (Ig) fragments. Despite the considerable progress in the understanding of MM biology, the molecular basis of the disease remains elusive. The initial transformation is thought to occur in a postgerminal center B-lineage cell, carrying a somatically hypermutated Ig heavy chain (IGH) gene. This plasmablastic precursor cell colonizes the bone marrow, propagates clonally and differentiates into a slowly proliferating myeloma cell population, all under the influence of specific cell adhesion molecules and cytokines. Production of interleukin-6 by stromal cells, osteoblasts and, in some cases, neoplastic cells is an essential element of myeloma cell growth, with the cytokine stimulus being delivered intracellularly via the Jack-STATand ras signaling pathways. While karyotypic changes have been identified in up to 50% of MM patients, recent molecular cytogenetic techniques have revealed chromosomal abnormalities in the vast majority of examined cases. Translocations mostly involve illegal switch rearrangements of the IGH locus with various partner genes (CCND1, FGFR3, c-maf) . Such events have been assigned a critical role in MM development. Mutations in coding and regulatory regions, as well as aberrant expression patterns of several oncogenes (c-myc, ras) and tumor suppressor genes (pl6, pl5) have been reported. Key regulators of programmed cell death (BCL-2, Fas), tumor expansion (metalloproteinases) and drug responsiveness (topoisomerase II alpha) have also been implicated in the pathogenesis of this hematologic malignancy. A tumorigenic role for human herpesvirus 8 (HHV8) was postulated recently, following the detection of viral sequences in bone marrow dendritic cells of MM patients. However, since several research groups were unable to confirm this observation, the role of HHV8 remains unclear. Translation of the advances in MM molecular biology into novel therapeutic strategies is essential in order to improve disease prognosis.
Introduction
Multiple myeloma (MM) is a plasma cell tumor derived from B-lineage clonogenic cells. Malignant plasma cells progressively infiltrate the bone marrow and produce a monoclonal immunoglobulin (Ig) (M-protein) or an Ig chain (M-component) [1] . The major pathophysiological consequences of advanced disease (overt myeloma) include osteolytic bone lesions, recurrent bacterial infections, anemia and renal insufficiency. MM presently accounts for almost 10% of all hematologic malignancies and approximately 1% of cancer-related deaths in Western countries [2] .
Monoclonal gammopathy of undetermined significance (MGUS) is a relatively common, potentially malignant condition, characterized by a serum M-protein concentration not exceeding 3.0 g/dl, and the presence of less than 10% plasma cells in the bone marrow [3] . Some patients with MGUS develop multiple myeloma, macroglobulinemia or amyloidosis. The actuarial rate of development of these diseases was 16% at 10 years and 40% at 25 years in 1 large series [4] . As long as the differential diagnosis of these plasma cell disorders is based upon quantitative criteria, regular follow-up of MGUS patients remains a necessity.
During the last decade, systematic research has led to a better insight in the molecular nature of MM. It has been postulated that the target cell for transformation is a more immature B cell than the plasma cell [5] . Such clonogenic precursors (plasmablasts) presumably colonize the bone marrow and may be detected as a small percentage among a majority of more differentiated myeloma cells, early in the disease. An increase in the proliferating plasmablastic population is observed in end-stage MM [6] . Homing to the bone marrow and differentiation of transformed plasmablasts into mature myeloma cells results from an interplay between the malignant cell population, the supportive marrow stroma and cells of the osteogenic lineage [7, 8] . interleukin (IL)-6 is the essential growth and survival factor for neoplastic cells, which express IL-6 receptor (IL-6R) molecules on their surface [9, 10] . Binding of the cytokine to its receptor triggers myeloma cell immortalization and/or proliferation through utilization of the Jak-STAT and ras signal transduction pathways [11, 12] .
Alterations in identified targets of IL-6 signaling, such as the nuclear oncogene c-myc, as well as in numerous other regulators of the cell-cycle machinery, have been implicated in MM pathogenesis and are associated with short survival or resistance to therapy [13, 14] . Molecular cytogenetic studies suggest that translocations of the Ig heavy chain (IGH) gene with various partner sites are the most common abnormalities among MM patients [15, 16] . The recently reported infection of stromal dendritic cells by human herpesvirus 8 (HHV8) may represent an additional piece of the myeloma pathogenesis puzzle, although a critical participation of the virus in tumor development is questioned by many groups [17, 18] . While none of the treatment protocols currently available against MM can be characterized as curative, disease prognosis has clearly improved over the last decade. High-dose chemotherapy followed by autologous hemopoietic stem-cell transplantation has proven significantly more effective than conventional chemotherapy, particularly in younger patients [19] . Allogenic bone marrow transplantation has been associated with complete clinical and molecular remissions in a significant percentage of patients, although transplant-related mortality limits a wider application of this approach [20, 21] . The ultimate goal of all investigators should be to translate the recent advances in the molecular pathogenesis of MM into novel, safer and more efficient therapeutic strategies.
Tumoral interactions with the bone marrow environment -IL-6 regulation of malignant cell behavior
The tendency of myeloma cells to reside in the bone marrow compartment during the main course of disease evolution is mainly attributable to their exclusive repertoire of adhesion molecules [22] . While neoplastic cells retain some of the phenotypic characteristics of normal plasmacytes, such as strong CD38 expression, they are readily distinguished from their physiologic counterparts by CD56 overexpression and absence of CD19 from their surface [4] . Determining the status of the proteins involved in cellular interactions has proven a useful tool for classifying MM cells into distinct differentiation stages. For instance, immature malignant cells that possess a high proliferative capacity exhibit CD21 expression, suggesting a role of this molecule in the initial attachment of myeloma progenitors to stromal cells that carry CD23 on their membrane [23] . On the other hand, CD49e/CD29 expression has been associated with slowly dividing mature myeloma cells, characterized by an increased potential for M-protein production. Additional surface markers, such as CD40, CD44, CD49d/CD29, CD54 and CD58, have been implicated in anchoring of tumor cells to the bone marrow environment [24] . Physical contact of dendritic and bone cells to malignant plasmacytes guarantees that the latter receive the fundamental cytokine signals in order to grow and survive. However, during advanced disease stages, a fraction of neoplastic cells become marrow-independent, resulting in extramedullary tumor localization [25] .
Cells of the osteogenic lineage have been assigned a critical role in MM pathophysiology. In response to myeloma cell contact, osteoblasts have been shown to release significant amounts of IL-6, which not only contribute to tumor growth, but also stimulate osteoclastmediated osteolysis [26, 27] . Lytic bone lesions represent a consistent finding among MM patients, resulting from an enhanced resorptive activity of osteoclasts coupled with decreased bone formation by osteoblasts [28] . A direct induction of bone resorption by myeloma cells has been proposed, through the secretion of osteoclastactivating factors, such as IL-lp" and parathyroid hormone-related protein (PTHrP) [29, 30] . Alternatively, hepatocyte growth factor (HGF) produced by malignant cells may indirectly promote osteoclast formation, via triggering of IL-11 expression by osteoblasts [31] .
Bisphosphonates are a group of drugs with longestablished inhibitory effects on bone destruction. It has been suggested that clodronate may suppress the production of propeptide of type I procollagen (PINP) by proliferating osteoblasts, thus impairing the osteolytic activity of osteoclasts. The latter may be monitored by the lower levels of type I collagen degradation product (ICTP) in the serum. Differentiated osteoblasts seem to respond to the decreased osteoclastic activity through underexpression of alkaline phosphatase (AP) [32] . On the other hand, long-term oral pamidronate treatment of MM patients has been shown to inhibit osteoclastmediated bone resorption without affecting osteoblastic function [33] . While recent clinical trials have revealed a beneficial action of bisophosphonates against myelomaassociated bone lesions, the most appropriate use of these agents is yet to be identified [34] .
Recent insights into the biological activities of a negative regulator of osteolysis, syndecan-1 (CD138), may introduce novel strategies for the management of MM cases in the future. Although expression of this heparan sulfate proteoglycan was initially thought to be limited on the surface of myeloma cells, recent studies have demonstrated its presence on normal plasma cells, as well [35, 36] . However, neoplastic cells have been shown to actively shed and release high amounts of the molecule, with serum levels of shed syndecan-1 representing a putative prognostic marker in MM, associated with M-protein concentration, tumor mass and short survival [37, 38] . Increasing in vitro and in vivo evidence supports a central role of syndecan-1 in MM pathobiology. The addition of intact purified CD138 to human myeloma cell lines (HMCLs) leads to a marked induction of apoptosis, downregulation of osteoclastogenesis and concurrent stimulation of osteoblast differentiation. Moreover, following injection in severe combined immune deficient (scid) mice, syndecan-1-transfected cells produce significantly less lytic bone lesions than cells expressing low levels of the molecule [39] . Finally, a role in inhibiting tumor invasion has been assigned to the membranebound form of syndecan-1, possibly through promoting the anchorage of malignant cells to their microenvironment, as well as by suppressing myeloma cell production of extracellular-matrix degrading enzymes [40] .
As previously mentioned, IL-6 has been established as a major growth factor for myeloma cells, both in vitro and in vivo [41, 42] . Although specific molecular events within transformed plasma cells often lead to autocrine IL-6 expression, the cytokine is predominantly secreted by non-malignant bone marrow cells, thus acting as a paracrine mediator of tumor development [43] [44] [45] . IL-6 belongs to a family of cytokines whose cell-surface receptors share the transducer element gpl30. The IL-6 family also includes oncostatin M, leukemia inhibitory factor, IL-11, ciliary neurotrophic factor and cardiotrophin 1, most of which are able to induce proliferation of HMCLs [46, 47] . Additional cytokines and growth factors have been implicated in MM pathogenesis, such as vascular endothelial growth factor (v-EGF) (through induction of bone marrow neovascularization), IL-5 and tumor necrosis factor a (TNF-a) (by triggering IL-6 production), IL-3 (by conferring IL-6 responsiveness) and IL-10 (possibly through upregulation of IL-11 receptor expression) [48] [49] [50] [51] . A more pivotal role has been assigned to IL-ip, which is secreted by myeloma cells and induces paracrine IL-6 production [52, 53] .
The transmembrane IL-6R consists of two distinct subunits: the IL-6-binding protein gp80 (IL-6Ra) and the signal transducer gpl30 (IL-6R(3) [54] . Both receptor chains are highly expressed on myeloma cells [55] . IL-6 initially forms a low-affinity complex with gp80, which in turns associates with gpl30, resulting in its homodimerization [56] . This event is followed by the phosphorylation of several gpl30 tyrosines by members of the unique class of Janus kinases (Jaks), such as Jakl, Jak2 and Tyk2 [57, 58] . Upon ligand binding, Jaks activate various signal transducers and activators of transcription (STATS), such as STAT1 and STAT3 [59] . These molecules form dimers, translocate to the nucleus and trigger the expression of target genes through binding to responsive elements within their promotors [60] . IL-6 has been shown to utilize the Jak-STAT pathway in order to transmit an anti-apoptotic signal in myeloma cells, partially by controlling the transcriptional status of c-myc [12, 61] . Nevertheless, there is also evidence of IL-6 triggering plasma cell proliferation through the ras-dependent mitogen-activated protein kinase (MAPK) cascade [62] .
Advances in IL-6 signal transduction have led to an improved understanding of the anti-proliferative effect of interferons (IFNs) on myeloma cells [63] [64] [65] . Type I (IFN-oc, IFN-P) and type II (IFN-oc) IFNs have been shown to inhibit the activation of key elements of the Jak-STAT and ras signaling pathways, although with varying effectiveness. IFN-disrupted events include transient tyrosine phosphorylation of gpl30 and its associated Jak kinases, binding of the tyrosine phosphatase PTP1D/ Syp to the adaptor protein Grb2, stimulation of the ERK2 MAPK, and synthesis of GTP-bound p2V as [11, 58] .
Cytogenetic abnormalities
Cytogenetic studies in MM have uncovered the unstable nature of the disease. Substantial heterogeneity in the chromosomal status of plasma cells is observed both among patients, as well as in intrapatient marrow examinations. The use of G-banding has revealed an incidence of complex abnormal karyotypes ranging from 30% to 50% of examined cases [66] [67] [68] [69] [70] . Aberrant patterns are accompanied by hyperdiploidy in approximately two thirds of patients [4, 71] . Conventional analysis has identified common chromosomal abnormalities, such as monosomy of chromosome 1, lp deletions, lq duplications, complete or partial deletions of chromosome 13, and rearrangements in chromosomes 2, 6, 8 and 11, whereas the most consistent finding has been the presence of the 14q+ marker [66, [72] [73] [74] . The latter observation provided the first indication of a translocated IGH gene, which had already been mapped to 14q32 [75] .
Over the last decade, modern molecular cytogenetic techniques, including metaphase and interphase fluorescence in situ hybridization (FISH) and long-distance polymerase chain reaction (LD-PCR), have allowed a more precise definition of chromosomal breakpoints and partner sites, as well as the demonstration of karyotypically silent abnormalities [76] [77] [78] [79] . Research groups applying such sensitive methodologies have identified a 14q32.3 translocation in up to 100% of patients and HMCLs, although reports of less prominent frequencies do exist [16, 77, [80] [81] [82] . Breakpoint analysis has revealed that the translocation predominantly occurs in IGH recombination switch regions, suggesting a late event in B-cell differentiation [80, 83] . The nearly universal presence of illegitimate IGH rearrangements supports the notion of an Ig sequence alteration forming a critical platform for MM development [77] .
A diverse, yet nonrandom, array of chromosomal partners have been unfolded for the 14q32.3 region, juxtaposing known or candidate proto-oncogenes to the IGH locus. In one third of cases, the partner site is Ilql3.3, also the hallmark of mantle-cell lymphoma (MCL) [16, 81, 83, 84] . However, in contrast to MCL, where the t(ll;14)(ql3.3;q32.3) translocation occurs through V(D)J-mediated recombination errors, in MM it is mostly produced by IGH switch aberrations [85, 86] . Despite the initial reports of breakpoint clustering within the BCL-1 locus, it has been shown that the sites of breakage are actually scattered throughout a region encompassing the cyclin Dl (CCND1) gene [75, 76, 84, 87, 88] . The translocation results in upregulation of cyclin Dl expression, possibly under the influence of an IGH enhancer region onto the adjacent oncogene [86, 89] . Patients harbouring the abnormality exhibit an aggressive clinical course [70] .
The recently demonstrated t(4;14)(pl6.3;q32.3) translocation represents another recurrent chromosomal abnormality [90] . It has been detected in up to 35% of MM patients and HMCLs with an IGH rearrangement, by means of Southern blot and FISH analysis [16, 81, 90, 91]. The 4pl6.3 breakpoints are located 50-100 kb centromeric of the fibroblast growth factor receptor 3 (FGFR3) gene, which is apparently deregulated [91, 92] . The translocation has been associated with high levels of FGFR3 expression, as well as with subsequent FGFR3 mutations that may render the generated protein constitutively active (90, 92) . The identification of two novel genes -transforming acidic coiled coil-containing gene 3 (TACC3) and multiple myeloma SET domain (MMSET) -in close proximity to 4pl6.3 breakpoints, suggests that t(4;14) may contribute to neoplastic transformation through more than one process [93, 94] . The 16q23.1 region is an additional common reciprocal partner of the IGH locus at 14q32 [81, 83, 95] . The translocation occurs through breakpoints dispersed 500 kb centromeric to the c-maf proto-oncogene and initiates elevated c-maf transcription [95] . The welldocumented Burkitt-type translocation [t(8;14)(q24;q32)] and its variants [t(2;8)(pll;q24) and t(8;22)(q24;qll)], which juxtapose the c-myc gene to the IGH, IgK and Ig^. loci, respectively, have also been observed in some patients (81, [96-98] . Although frequently deregulated in MM, c-myc is only sporadically translocated to an Ig locus [16] . Numerous other donor sites, participating in add(14)(q32) chromosome formation, have been noted. Some have been shown to carry known oncogenes, such as 6p25 (MUM1/IRF4), 9pl3 (PAX5), 18q21 (BCL-2) and 19ql3 (BCL-3), while for most, a deregulated gene has not been established, as in the cases of 6p21, 12pll, 12pl3, 12q24, 16q24 and Xq28 [77, 78, 82, [99] [100] [101] [102] . Translocations that are independent of the IGH locus involve multiple chromosomal regions, such as lpll, Ip36, Iq21, 16pll and 19pl3 [70] .
Deletions or monosomy of chromosome 13 have recurrently been observed in MM and have been linked to a shorter survival compared to other abnormalities [69-71, 103, 104] . The most frequently deleted marker has been D13S319, residing between the retinoblastoma (RBI) and D13S25 loci at 13ql4, a finding that suggests the existence of a candidate tumor suppressor gene telomeric of RBI [103] . A role of monosomy 13 in MGUS progression to overt MM has recently been proposed [104] . Table 1 highlights the most common cytogenetic abnormalities in MM.
Cell-cycle and apoptotic deregulationdevelopment of drug resistance
Numerous alterations of genes and proteins involved in the cellular response to external and internal stimuli have been reported in MM ( Table 2 ). The significance of these events in impairing normal cell-cycle progression and programmed cell death, as well as in conferring resistance to chemotherapeutic agents, is currently under intense investigation. This section comprises a review of structurally and functionally deranged molecules, presented in the order of their sequential participation in signal transduction from the membrane to the nucleus. In slowly proliferating tumors, such as MM, apoptotic downregulation represents an essential mechanism of malignant cell expansion. In a key process of maintaining immune homeostasis, activated or transformed cells expressing the Apo-1/CD95 (Fas) surface antigen become susceptible to apoptotic destruction by effector cells that carry Fas ligand (FasL) [148] . Significantly reduced levels of plasma cell Fas expression, as well as loss-of-function mutations in the encoding gene, have Abbreviations: OE -overexpression; AS -alternative splicing; PC -proteolytic cleavage; D/AE -downregulation or absence of expression; HM -hypermethylation; DEL -deletions; IL-6 E -IL-6 induced expression; mt-CR -mutations in coding regions; mt-NCR -mutations in noncoding regions; NA -not assessed due to limited number of studies; LOH -loss of heterozygosity. a Data presented in order of descending frequency. been noted in some myeloma patients and HMCLs [133, 134] . This finding suggests that impairment of the FasFasL system may contribute to the pathogenesis of MM. An additional protein involved in cellular interactions, the tyrosine phosphatase PTEN/MMAC1, may regulate malignant cell invasion through its action at focal adhesions [149] . Alterations in the PTEN tumor suppressor gene, located on chromosome 10q23.3, are more frequently observed in epithelial than lymphoid neoplasms. Intron deletions in PTEN have indeed been found in only a small percentage of MM cases [147] .
A more critical role has been assigned to a family of extracellular-matrix degrading enzymes, known as matrix metalloproteinases (MMPs), which are potent inducers of neovascularization and bone resorption. Some MMPs are secreted in soluble forms, while others reside on the cell surface as transmembrane proteins [150] . Overexpression of the MMP-9 gelatinase by myeloma cells has been a common observation, especially in patients underexpressing syndecan-1 [37, 40] . Malignant plasmacytes are also characterised by high transcriptional levels of the MMP-2 gelatinase, mainly in advance disease stages [117] . Recent in vitro evidence suggests that human myeloma cells are capable of inducing the conversion of pro-MMP-2 -produced by the tumor environmentinto its activated form, through a matrilysin-mediated process [151] . Furthermore, tumor cells have been shown to stimulate stromal cell production of the MMP-1 collagenase [152] . The tissue inhibitor of metalloproteinase (TIMP)-l and TIMP-2 are the best characterised regulators of MMP activity, thus comprising potential agents against myeloma progression [153] .
Events challenging the integrity of plasmacyte membrane receptors may be of increased importance in MM pathogenesis. As previously mentioned, upregulated expression of FGFR3 is a frequent consequence of the t(4;14)(pl6.3;q32.3) translocation. Point mutations in the FGFR3 gene have also been noted, generating a receptor that maintains its activity in the absence of ligand [90, 92, 132] . Overexpression of fibroblast growth factor receptor 2 (FGFR2), which has been demonstrated in patients with active disease, is thought to confer an increased angiogenic potential to myeloma cells [146] . High bone marrow microvascular density correlates with poor prognosis and drug resistance. Thalidomide, a potent angiostatic agent can induce marked responses in some patients with refractory multiple myeloma, including those who relapse after highdose chemotherapy [154, 155] .
Of particular interest is the functional status of the soluble form of IL-6Ra (sIL-6Ra) released by plasma cells. This molecule acts as an agonist of IL-6 responsiveness via binding to the extracellular N-terminal domain of gpl30 [156] . Production of sIL-6Ra is almost always elevated in MM, and correlates strongly with tumor expansion in vivo, as well as immortalization and osteoclast formation in vitro [105, 157] . The mechanisms involved in sIL-6Roc production are alternative mRNA splicing and proteolytic cleavage [106] . The latter process is mediated by a non-matrix-type metalloprotei-nase, which is susceptible to inhibition by TIMP-3 and a hydroxamate-based agent in cell culture [107] .
Multidrug resistance (MDR) presents a major obstacle in successful chemotherapeutic treatment of MM. 'Classical' MDR is based on the activities of the MDR1 gene product, the 170-kD transmembrane glycoprotein P (Pgp) [158] . Expression of this ATP-dependent drug-efflux pump has been observed in a minority of myeloma patients, pointing towards the frequent occurrence of 'non-Pgp' MDR in the disease [108, 142] . The displayed drug evasion may be partially due to the multidrug resistance-associated protein (MRP), a 190-kD membrane-bound molecule, capable of directly extruding cytotoxic agents from the cell, as well as initiating their sequestration into intracellular compartments [158] . Several HMCLs have been shown to overexpress MRP [142, 143] . An additional type of resistance, the one directed against glucocorticoids (e.g., dexamethasone, DEX), is to some extent attributable to defects of the glucocorticoid receptor (GR). Alternative splicing and deletions of the GR gene have been demonstrated in vitro, resulting in the production of dysfunctional receptor isoforms, which allow myeloma cells to escape hormonal effects [144, 145] .
Among the plethora of intracellular signal transducers, the ras family of GTP-binding proteins are the most commonly deranged in human tumors. Base substitutions in the N-and K-ras oncogenes, primarily at codons 12, 13 and 61, have been detected in up to 50% of MM cases, and are associated to an aggressive clinical course [125] [126] [127] . While the presence of K-ra.s alterations significantly decreases patient survival, activating mutations in N-ras result in IL-6-independent growth of myeloma cells in vitro [159] . On the other hand, aberrant Ha-ras expression may contribute to an increased autocrine secretion of IL-6, possibly through hyper-activation of cytokine transcriptional inducers, such as c-Jun and NF-IL6 [43, 128, 129] . Molecular analysis in newly diagnosed cases, as well as in patients with advanced stage disease, has revealed that ras mutations may represent early, yet ongoing events in MM [4, 105] .
The 26-kD oncoprotein BCL-2 is a well-characterised inhibitor of programmed cell death, residing on the outer mitochondrial membrane, endoplasmic reticulum and nuclear envelope. The function of BCL-2 is mainly counteracted by Bax, while two other members of the same family, BCL-X L and BCL-X S , act in an anti-and pro-apoptotic fashion, respectively [160] . High levels of BCL-2 expression have been detected in approximately three quarters of myeloma patients [109, 111] . Slowly proliferating myeloma cells from most MGUS and newly diagnosed MM cases possess an elevated BCL-2 content, which suggests an early involvement of this anti-apoptotic factor in the disease [161] . In contrast, BCL-X L is preferentially overexpressed by rapidly dividing malignant plasma cells from extramedullar lesions of patients at advanced clinical stage [109] . The presence of BCL-X L has been linked to MDR, whereas BCL-2 has been particularly implicated in DEX-evasion [110, 162] . The nearly ubiquitous absence of Bax and BCL-X S from neoplastic cells of MM patients has also been assigned a role in the development of MDR phenotypes [109, 110] . The participation of Bax in Fasmediated apoptosis has been demonstrated in vitro, indicating that apoptotic impairment in myeloma cells with normal Fas expression may stem from Bax downregulation [133] .
The nuclear enzyme topoisomerase II alpha (Topo-IIoc) is actively involved in the lethal action of cytotoxic drugs, while downregulation of its expression has been associated with 'atypical' MDR in various malignancies [158] . Myeloma cells underexpress Topo-IIa, both in vitro and in vivo, possibly due to a reduction in the activity of the CP-1/NF-Y transcription factor [108, 143, 163] . Another resistance marker, the p-class glutathione S-transferase, is highly expressed in some MM cases, however, with no significant effect on clinical response [108] .
Nearly 30% of MM patients express increased levels of cyclin Dl, primarily resulting from an IGH-CCND1 translocation [16, 81, 89] . Cyclin Dl is preferentially expressed in morphologically immature, highly proliferating myeloma cells, which acquire additional aberrations in cell-cycle regulatory molecules during disease progression [130, 131] . The transcriptional status of the INK4 family of cyclin-dependent kinase inhibitors (CDKIs) has been an attractive field of research. Silencing by 5' CpG-island hypermethylation of the^<5 INIC4A and /?/5 IN1C4B genes, located on chromosome 9p21, has been detected in 40%-80% of MM cases [112, 113, 116] . Underexpression of pJ6 mK4A in particular, has been associated with an increased risk of developing plasma cell leukemia [114] . Although mono-or bi-allelic deletions of INK4 CDKIs represent recurrent events in B-lymphoid malignancies, they have been rarely noted in MM [113, 115] . Two additional CDKIs,/?2/ WAF1/CIPI and/?27 Klpl , are absent from both neoplastic and normal plasma cells in vivo, while only expressed in certain HMCLs [130, 164, 165] .
The retinoblastoma-susceptibility (RBI) tumor suppressor gene at 13ql4.2 encodes a pivotal cell-cycle regulator, implicated in a variety of human tumors. Mono-allelic deletions of RBI are common in MM, though without any consequence on pRb expression. On the other hand, loss of heterozygosity leading to complete RBI inactivation is a rare event, associated with advanced-stage disease in vivo and increased autocrine IL-6 production in vitro [135] .
The p53 tumor suppressor gene, located on chromosome 17pl3, encodes a multifunctional 53-kD protein, involved in cell-cycle control at checkpoints, maintenance of genomic integrity, apoptotic regulation and differentiation decisions. Mutations in p53 comprise the most frequent genetic alterations in human neoplasms [166] . However, MM patients rarely carry p53 irregularities [136] [137] [138] . Interestingly, p53 mutations represent common events in vitro, which suggests that they prob- ably originate during the establishment or prolonged culture of HMCLs [138, 139] . A pathogenic role of p53 has recently been proposed in cases overexpressing cyclin Dl [167] . The MDM2 gene, mapped at 12ql3-14, encodes a phosphoprotein that forms a regulatory feedback loop with p53. Constitutive MDM2 expression occurs more frequently in cell lines than myeloma patients, being usually accompanied by alterations in p53 [140, 141] . The proto-oncogene c-myc, residing on chromosome 8q24, encodes a nuclear transcription factor with a vital role in the regulation of the cell-cycle machinery and apoptosis. Upregulation of c-myc expression is a common event in MM, most likely as a consequence of enhanced IL-6 signaling [12, [118] [119] [120] [121] . In only a small number of cases, aberrant c-myc activation results from Burkitttype translocations, where it correlates with an aggressive disease phenotype [96] [97] [98] . Finally, point mutations in coding and regulatory regions have been detected in some HMCLs, leading to increased binding of c-myc to its downstream partners [122] [123] [124] .
The controversial role of human herpesvirus 8
The recently identified Kaposi's sarcoma-associated herpesvirus or human herpesvirus type 8 (HHV8) belongs to the family of rhadinoviruses and has been established as a major etiological agent for all clinical forms of Kaposi's sarcoma (KS), primary effusion lymphoma and multicentric Castleman's disease [168] [169] [170] [171] .
The HHV8 genome contains an array of cell-homologous genes, which are thought to represent remnants of previously infected hosts during viral evolution, and their products participate in inflammation, cell-cycle progression and apoptosis. This type of molecular 'piracy' is a popular strategy among rhadinoviruses and constitutes a determinant of their pathogenicity [172] .
Given the IL-6-dependent nature of formerly recognised HHV8-related tumors, an implication of the virus in MM seemed conceivable. The first sign of HHV8 infection emerged through PCR amplification of viral sequences in a series of cultured bone marrow stromal cells from myeloma patients, directly followed by in situ hybridization evidence in trephine biopsies [17, 173] . The initial scientific enthusiasm was soon replaced by skepticism, due to the inability of several study groups to confirm the observations described in the original report [174] [175] [176] [177] . An appealing explanation for the ongoing controversy could be based on the low number of HHV8 genome copies in infected cells [178] . This feature implies that several parameters, such as modifications in stromal cell-culture conditions and contamination of bone marrow aspirates by non-infected malignant cells, may compromise the sensitivity of viral detection [179] . At this time, data supporting the presence of HHV8 in bone marrow dendritic cells of MM patients have accumulated. The observation of viral sequence variations among examined patients seems to exclude the possibility of PCR contamination [18] . Furthermore, studies demonstrating stromal cell expression of virally encoded products, such as the homologues of interferon regula-tory factor 1 (v-IRF-1), interleukin-8-receptor (v-IL-8R) and, in particular, IL-6 (v-IL-6), may not be easily discarded [180] .
On the other hand, numerous groups have questioned the actual importance of HHV8 in MM pathogenesis. Detection of viral sequences has not been restricted to myeloma patients, with some bone marrow specimens originating from healthy individuals being infected as well [181] . Even researchers arguing in favour of the recurrent presence of HHV8 in MM cases have recently shown that infected dendritic cells retain their normal antigen presenting function and immunophenotypic characteristics [18] . Moreover, the low prevalence of antibodies in serologically screened patients has not been fully explained [182, 183] . Whether such findings result from a generalized myeloma-induced hypogammaglobulinaemia or a distinct viral mechanism of immune evasion needs further investigation [178] . Recent data suggest that PCR positivity for presumed HHV8 may actually be due to the presence of EBV-infected lymphoblastoid cells with plasmacytoid features [184] .
Conclusions
Molecular analysis in HMCLs and patients at different disease stages has unraveled a sequence of events that may contribute to MM development (Figure 1 ). It has become evident that the tumor constitutes a paradigm of the 'multiple hit' concept, with the critical genetic error presumably being an illegitimate IGH rearrangement in a post-germinal center B cell. Transformed cells acquire further aberrations in the function of membranebound, cytosolic and nuclear factors during disease progression with varying impacts on tumor expansion and resistance to therapy. A fundamental novelty of MM lies in the significance of non-malignant marrow constituents in tumor progression. Stromal cells seem capable of inducing and sustaining myeloma cell growth, partially through the production of human, and possibly viral, IL-6. In addition, bone cells respond to malignant cell adhesion by secreting factors that contribute to myeloma cell proliferation, osteolysis and tumor invasion.
New therapeutical strategies are emerging from our improved knowledge of the biology of myeloma. Highdose chemotherapy followed by autologous or allogenic transplantation, along with adjunctive therapies targeting the myeloma cell microenvironment, such as bisphosphonates and thalidomide, have yielded promising results and have improved patients' survival. Future efforts should aim in eliminating residual disease, sustaining complete remission and treating each case individually. Monoclonal antibody therapy directed against surface antigens of malignant plasma cells and circulating myeloma precursors, as well as DNA vaccination designed to trigger immune responses against the tumor, are currently being explored [185, 186] . The M-component may represent an idiotypic target of particular interest [187] . Based on the major advances in our understanding of MM pathogenesis, the objective of successful therapy seems less distant than a decade ago.
